

## MICROBIOLOGICAL ACTIVITY OF DERIVATIVES 4-CHLORO-7-HYDROXY-CHROMEN-2-ONE COMPARE WITH STANDARD DRUGS

Aziz BEHRAMI

<sup>1</sup>University''Isa Boletini'' of Mitrovica, Kosovo

### Abstract

*Nucleophilic substitution and electrophilic of 4-Chloro-7-hydroxy-chromen-2-one are yielded compounds 4-(2,6-Dihydroxy-pyrimidin-4-ylamino)-2-oxo-2H-chromen-3-sulfonyl chloride (1a), {4-[Bis-(2-chloro-ethyl)-amino]-7-hydroxy-2-oxo-2H-chromen-3-yl}-phosphonic acid (2a), (3-Formyl-7-hydroxy-2-oxo-2H-chromen-4-yl)-dithiocarbamic acid(3a). Characterization synthesized chemical compounds was done by FTIR and NMR spectra and analysis of chemical composition of elements. Monitorization of antibacterial effect of synthesized compounds a,b,c was monitored at concentrations 2, 3, 5 mg/ml in three bacterial microorganism cultures: Staph. Aureus, E-coli and Bac. Cereus. The antibacterial activity of synthesized compound was compared to antibacterial activity of standard antibiotics cephalaxine and streptomycin.*

**Keywords:** derivatives of 4-Chloro-7-hydroxy-chromen-2-one, antibacterial activity, S.Aureus, E.coli, Bacillus cereus, streptomycin.

### Introduction

Several coumarine derivative compounds was reported as a high antimicrobial, anticancer and anticoagulant activity. [1-4]. Several years ago some of coumarine analoge compounds of 3,4-disubstituted coumarins were define as antiomicrobial such as 2H-[1]-benzopiran-2-one [5,6].

For this reason coumarine derivatives was under intensive investigations especially for organic synthesis. Otherwise substitution of coumarine especially in position 3 and 4 was subject of research interests and this substitution of coumarine was rapid increases their biological activity [7]. Therefore, our research interest is starting from 4-Chloro-7-hydroxy-chromen-2-one to synthesize a several novel compound to improve their antibacteriological activity using as a comparative compounds standard commercial antibiotic.

### Experimental Chemistry

4-(2,6-Dihydroxy-pyrimidin-4-ylamino)-2-oxo-2H-chromene-3-sulfonyl chloride **a**, {4-[Bis-(2-chloro-ethyl)-amino]-7-hydroxy-2-oxo-2H-chromen-3-yl}-phosphonic acid **b**, (3-Formyl-7-hydroxy-2-oxo-2H-chromen-4-yl)-dithiocarbamic acid **c**, are synthesized.

### Materials and Methods


After lab synthesis of compound in interests wrote (**a**, **b**, **c**), was characterized using several parameters such as melting point, FTIR-Spectroscopy, <sup>1</sup>H NMR, <sup>13</sup>C NMR spectra and finally analysis of elements in synthesized compounds. Used Equipment for melting point was,

Fisher Scientific 2555, Electrothermal equipment. Fourier Transform Infrared spectra were analysed in region from 400-4000  $\text{cm}^{-1}$  using KBr pellets on a FT-IR Shimadzu IRAffinity-1 resolution 4  $\text{cm}^{-1}$  and 32 scan.  $^1\text{H}$  NMR spectra were done by Bruker UNITY plus-500 'NMR 1' spectrometer dissolved in DMSO- $d_6$  and TMS as the internal standard compounds ( $\sigma = 0,00$  ppm). Mass spectra were taken on a LKB 9000 mass spectrometer. Analysis of elements was done by Perkin-Elmer 240 BCHN analyzer. Purity monitoring of the synthesized compounds was checked by TLC using Silicagel plate using mobile phase mixture of solvents benzene, toluene, glacial acetic acid (80:10:10).

**Preparation of 4-(2,6-Dihydroxy-pyrimidin-4-ylamino)-2-oxo-2H-chromene-3-sulfonyl chloride (a)**

For synthesized of first derivative is used 5g 4-Chloro-7-hydroxy-chromen-2-one as substrat dissolved in a 100 ml flask than mixed with 10 ml ethanol, and 2ml N.N DMF, where was catalysed with 1ml triethanolamine.


Synthesis was continue and for 7 hours heating under reflux at 120 °C. Precipitate material than was separated by filtration from the hot mixture, washed with ethanol, than drying in exicator and crystallized from N,N-Dimethyl formamide, synthesized orange crystals was in 80% yield and measured of melting point 286 °C.



**Fig. 1.** 4-(2,6-Dihydroxy-pyrimidin-4-ylamino)-2-oxo-2H-chromene-3-sulfonyl chloride (a)

**Preparation of {4-[Bis-(2-chloro-ethyl)-amino]-7-hydroxy-2-oxo-2H-chromen-3-yl}-phosphonic acid (b)**

For synthesized of (b) are used 2g 4-Chloro-7-hydroxy –chromen-2-one: add 2g Bis-2(chloro-ethyl) amine in a 100 ml flask dissolved in 6ml ethanol and 3ml of phosphoric acid. Under reflux reaction was heated for 10 hours at 80 °C. Syntheetized yellow crystals are separated by filtration and dried at normal room temperature. It is necessary to do recrystallization using ethanol as a solvent which will obtain yellow crystals compounds with 65 % yield and measured melting point, 230 °C.




**Fig. 2.** {4-[Bis-(2-chloro-ethyl)-amino]-7-hydroxy-2-oxo-2H-chromen-3-yl}-phosphonic acid (b)

**Preparation of (3-Formyl-7-hydroxy-2-oxo-2H-chromen-4-yl)-dithiocarbamic acid (c)**

Added 2 g of 4-Chloro-7-hydroxy-chromen-2-one and dissolved in 100 ml flask were mixed with solvent 6ml ethanol and 1 ml triethanolamine as a catalysts, than add 4ml Dithiocarbomidacid, and 3ml formic acid. All mixture was heated for 22 hours under reflux at 100 °C in oil bath. After this flask was placed in an ice bath for 1h until obtaining white crystal. After product filtration it was recrystallized using CH<sub>3</sub>CN as a solvent .

The recrystallization gave a white product at 90% yield, and measured meltingpoint was 290 °C.



**Fig. 3.** (3-Formyl-7-hydroxy-2-oxo-2H-chromen-4-yl)-dithiocarbamic acid (c)

**Table 1.** Characteristics and analytical data of the complexes

Comp	Yield %	m.p	M.F	C%	S%	Cl%	H%	N%	O%
a	80	286°C	C <sub>13</sub> H <sub>8</sub> ClN <sub>3</sub> O <sub>6</sub> S	42.23	8.67	9.59	2.18	11.36	25.96
				42.18	8.60	9.50	2.15	11.38	25.98
b	65	230°C	C <sub>13</sub> H <sub>14</sub> Cl <sub>2</sub> NO <sub>6</sub> P	40.86		18.59	3.69	3.67	25.12
				40.50		18.50	3.62	3.60	25.10
c	90	290°C	C <sub>11</sub> H <sub>7</sub> NO <sub>4</sub> S <sub>2</sub>	46.97	22.80		2.51	4.98	22.75
				46.80	22.71		2.45	4.90	22.70

**Antibacterial activity**

All synthesized and characterized purified compounds (a,b,c) was tested for their antibacterial activity apply in three different bacterial culture: Staphylococcus aureus, E.Coli and B.cereus. Investigation was applied Kirby-Bayer method to test the antibacterial activity of compounds. [8].

**Table 2.** Antibacterial activity- Staphylococcus aureus

Compound	Inhibition zone (mm)		
	2mg/ml	3mg /ml	5mg/ml
a	8,5	11	15,5
b	9,2	15,5	17
c	7,5	10,8	13,5
Cefalexine	9	9	9 10 µg
Streptomycine	20	20	20 10 µg

**Table 3.** Antibacterial activity – E.Coli

Compound	Inhibition zone (mm)		
	2mg/ml	3mg /ml	5mg/ml
a	7,8	10,2	12,7
b	8,8	13,2	14,4
c	10	11,6	14,8
Cephalexine	9	9	9 10 µg
Streptomycine	23	23	23 10 µg

**Table 4.** Antibacterial activity – *Bacillus cereus*

Compound	Inhibition zone (mm)		
	2mg/ml	3mg /ml	5mg/ml
a	10.9	14.3	22.7
b	9.1	14.7	21.6
c	8.7	10.8	12.9
Cephalexine	9	9	9 10 µg
Streptomycine	23	23	23 10 µg

## Results and Discussion

All three synthesis of coumarine compounds was tested for their antibacterial activity in comparison with standard antibiotics (cefalexine and streptomycine). In all three culture all three synthesized compounds have higher activity in comparison with cefalexine and all three compounds are strongly competitive with streptomycine especially in *Bacillus cereus*.

The structure of 4-Chloro-7-hydroxy-chromen-2-one derivatives (a,b,c) were determined from their IR,  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR spectra and their melting points as follows.

**For (1a); IR bands (KBr, cm<sup>-1</sup>)** 3500 stretch (OH); 3400 stretch (N-H), 3000 stretch (CH-arom), 1742 stretch (C=O), 1580-1510 stretch (C=C aromatic), 1410-1350 stretch (SO<sub>2</sub>Cl); stretch (S-Cl).

**$^1\text{H}$  NMR (DMSO-d<sub>6</sub>)  $\delta$  ppm,** 4.9 ppm s(H-OH), 4.0 ppm h(NH) 5.0-5.5 ppm (2H, 2OH); 7.20 ppm -7.63 (4H arom).

**$^{13}\text{C}$  NMR (DMSO)  $\delta$  ppm;** 121.3 -127.8 ppm m(5.C aromatic); 150.8 ppm (C,C-O); 162.0 ppm (C,C=O); 167 ppm (C,C-N); 164.4 (C,C-OH) 166 ppm (C,C-O); 89 ppm (C,C-SO<sub>2</sub>)

**For (2a) IR bands (KBr, cm<sup>-1</sup>)** 3480 stretch (O-H stretch); 3418 stretch (N-H); 3000 stretch (C-H aromatic); 2870 stretch (C-H stretch); 1740 stretch (C=O); 1600 stretch (C=C aromatic); 770 stretch (C-Cl).

**$^1\text{H}$  NMR (DMSO-d<sub>6</sub>)  $\delta$  ppm** 2.83 ppm d(4H, CH<sub>2</sub>); 3.50 ppm d(4H, 2CH<sub>2</sub>Cl); 5.0 ppm s(H, OH); 2.0 ppm d(2H-2OH); 6.5-7.5 ppm m(4H - aromatic).

**$^{13}\text{C}$  NMR (DMSO)  $\delta$  ppm** 53.3 ppm (C, CH<sub>2</sub>); 45.1 ppm (C, CH<sub>2</sub>Cl); 89.8 ppm (C, C-P); 181 ppm (C, C-N); 152.2 ppm (C, C-O); 162 ppm (C, C=O); 156.9 ppm (C, C-OH) 113.4-128.0 ppm (3C aromatic).

**For (3a) IR bands (KBr, cm<sup>-1</sup>)** 3400 stretch (O-H, stretch.), 3380 stretch (N-H, stretch.), 2990 stretch (C-H aromatic), 2870 stretch (C-H), 1740 stretch (C=O); 1600 stretch (C=C aromatic), 1240 stretch (C=S); 1050 stretch (C-O), 1030 stretch (C-S), 752 stretch (C-S)  **$^1\text{H}$  NMR (DMSO-d<sub>6</sub>)  $\delta$  ppm** 1.8 ppm (H, SH), 2.5 ppm (H, NH), 5.0 ppm s(H, OH), 6.67-7.46 ppm (3H aromatic); 9.68 ppm (H-CHO).

**$^{13}\text{C}$  NMR (DMSO)  $\delta$  ppm** 108.5-128.4 ppm (4. C aromatic); 152.2 ppm (C, C-O); 156.9 ppm (C, C-OH); 181 ppm (C, C-NH); 190 ppm (C, CHO); 194.7 ppm (C, C=S).

## Conclusion

Novelty coumarine derivatives compounds of 4-(2,6-Dihydroxy-pyrimidin-4-ylamino)-2-oxo-2H-chromene-3-sulfonyl chloride, 4-[Bis-(2-chloro-ethyl)-amino]-7-hydroxy-2-oxo-2H-chromen-3-yl]-phosphonic acid, 3-Formyl-7-hydroxy-2-oxo-2H-chromen-4-yl) dithiocarbamic acid were synthesized and characterized for their chemical properties and then evaluated for their anti-fungal and anti-bacterial activities for the first time.

## Acknowledgements

The authors thank Prof. Kozeta Vaso, University of Tirana for  $^1\text{H}$  NMR spectrum and elemental analyses.

**References**

- [1] I Kostova, *Synthetic and natural coumarine as cytotoxic agents* **Curr Med chem Anticancer Agents**, **5**, 2005, pp. 29-46.
- [2] K. C. Fylaktakidou, D. J. Hadjipavlou – Litina, K. E. Litinas and D. N. Nicolaidis, *Natural synthetic coumarine derivatives with anti-inflammatory/antioxidant activities* **Curr Pharm Des**, **10**, 2004, pp. 3813-3833.
- [3] M. J. Matos, S. Vazques-Rodrigues, E. Uriarte, L. Santana and D. Vina, *MAO inhibitory activity modulation :3-Phenylcoumarine versus 3-benzoylcoumarine*, **Bioorg Med Chem Lett**, **21**, 2011, pp. 4224-4227.
- [4] T. Ojala, S. Remes, P. Haansuu, H. Vuorela and R. Hiltunen, *Antimicrobial activity of some coumarine containing herbal plants growing in Finland*, **J Ethenopharmacol**, **73**, 2000, pp. 299-305.
- [5] Z. M. Nofal, M. I. El-Zahar and S. S. Abd El –Karim, *Novel Coumarine Derivatives with Exected Biological Activity*, **Molecules**, **5**, 2000, 99-113.
- [6] M. D. Aytemir, R. C. Hider, D. D. Erol, M. Ozal. M. Ekizoglu and J. Turk, *Synthesis of new antimicrobial of pyranones and pyridinones*, **Chem.**, **27**, 2003, p. 445.
- [7] N. Batra, S. Batra, A. Prateek and B. N. Prakash, *Prevalence of preventable medication – related hospitalizations in Australia : an opportunity to reduce harm*. **Int. J. Pharm.** **24**, 2012, pp. 239-249.
- [8] A. L. Barry, F. Garcia and L. D. Thrupp, *An improved single-disk method for testing the antibiotic susceptibility of rapidly-growing pathogens*. **Am. J. Clin. Pathol.**, **53(2)**, 1970, pp. 149-158.
- [9] R. M. Mohareb, Z. Ho Jonatan and A.A Mohamed, *The Reaction of cyanoacetyl hydrazide with cyclopentanone: synthesis of coumarin, pyridine and thiazole derivatives*, **Egyptian Journal Of Chemistry**, **52(3)**, 2007, pp. 349-360.
- [10] M. M. Saghier, E. L. Naili, M. B Rammash, B. K Saleh N. A and Kreddan K. M. *Synthesis and antibacterial activity of some new fused chromenes* 2007 **Arkivoc** **16**:83-91
- [11] S H Lee, D. S. Shin, J. S. Kim, B. Oh and S. S. Kan, *Antibacterial compounds from the leaves of Acanthopanax senticosus*, **Arch. Pharm. Res.**, **26**, 2003, pp. 40-42.
- [12] K. B. Vyas, K. S. Nimavat, G. R. Jani and M. V. Hathi, **Orbital**, **1**, 2009, p. 183.
- [13] A. V. Abyshev, V. A. Gimdein, E. V. Semenov, E. M. Agev, A. A. Abdulla, A. Zade and F. Gueseinov, **Pharm. Chem. J.**, **40**, 2006, p. 607.
- [14] M. M. El Saghier, M. B. Naili, M. Kh. Rammash, N. H. Saleh and K. M. Kreddan, *Synthesis and antibacterial activity of some new fused chromenes* **Arkivoc**, **xvi**, 2007, pp. 83-91.
- [15] Z. Nofa, M. El-Zahar and M. Abd El Karim, **Molecules**, **5**, 2000, p.99.
- [16] K. C. Chaluvvaraju, C. Ishwarbhat and K. Asian, **J. Chem.**, **20**, 2008, p. 4335.
- [17] R. Ra Kali, S. Grworamma and B. Suresh, **Asian J. Chem.**, **20**, 2008, p. 5289.
- [18] A. Mohammed Ashraf and S. H. Mohammed, *Synthesis, Characterization and Biological activity of new derivatives of Chromen-2-one* . **Boorg. Med. Chem. Lett.**, **17**, 2009, p. 3314.
- [19] Z. M. Nofal, M. El-Zahar and S. Abd El-Karim, *Novel coumarin derivatives with expected biological activity*, **Molecules**, **5**, 2000, pp. 99- 113.

- [20] K. B. Vyas, K. S. Nimavat, G. R. Jani and M. V. Hathi, *Synthesis and microbial activity of coumarin derivatives metal complex: An in vitro evaluation*, **Orbital**, **1**, 2009, pp. 183-192.

---

*Received: December 9, 2018*

*Accepted: February 24, 2019*